What is the translation of " RANDOMISATION " in Slovenian?

• randomizacija
• randomizaciji
• randomizacije
• randomizacijo
• naključni razvrstitvi

Examples of using Randomisation in English and their translations into Slovenian

Weeks after randomisation.
Tednov po randomizaciji.

IIa: at least one well-designed controlled study without randomisation.
B IIa: vsaj ena dobro zasnovana nadzorovana raziskava brez randomizacije.

Months from Randomisation.
Meseci od randomizacije.

In all patients, assessment of efficacy was 8 weeks after the randomisation.
Pri vseh bolnikih so ocenili učinkovitost zdravljenja 8 tednov po randomizaciji.

Months since randomisation.
Meseci od randomizacije.

All patients were followed-up until withdrawal or up to 3 years after randomisation.
Vse bolnike so spremljali do umika iz študije ali do 3 leta po randomizaciji.

Time since randomisation(week).
Čas od randomizacije(teden).

Randomisation was stratified by HCV genotype(1, 2, 3, 4, 5, 6 and indeterminate).
Randomizacija je bila stratificirana po genotipu HCV(1, 2, 3, 4, 5, 6 in nedoločen).

IIa Evidence obtained from at least one well designed controlled study without randomisation.
B IIa: vsaj ena dobro zasnovana nadzorovana raziskava brez randomizacije.

Time since Randomisation(Week) IDegLira=Xultophy.
Čas od randomizacije(teden).

Includes patients who received at least one dose of blinded medicinal product after randomisation.
Zajema bolnike, ki so prejeli vsaj en odmerek prikritega zdravila po naključni razvrstitvi.

Randomisation was stratified by screening HIV-1 RNA level(≤ 100,000 copies/ml orgt; 100,000 copies/ml).
Randomizacija je bila stratificirana s presejanjem ravni RNA HIV-1(≤ 100.000 kopij/ml aligt; 100.000 kopij/ml).

Post-hoc efficacy analysis in patients who maintained a high or very high DRL at randomisation.
Post hoc analiza učinkovitosti pri bolnikih, ki so ohranili visoko ali zelo visoko DRL pri randomizaciji.

At randomisation, 70% of patients were NYHA class II, 24% were class III and 0.7% were class IV.
Ob randomizaciji je imelo 70% bolnikov srčno popuščanje razreda II, 24% razreda III in 0,7% razreda IV po klasifikaciji NYHA.

The primary outcome measure was overall survival defined as the time from randomisation until death from any cause.
Primarni cilj preskušanja je bilo celokupno preživetje, definirano kot čas od randomizacije do smrti iz kateregakoli vzroka.

Randomisation was stratified by HCV genotype(1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.
Randomizacija je bila stratificirana glede na genotip(1, 2, 4, 6 in nedoločen) in prisotnost ali odsotnost ciroze.

During SET, patient diaries were recorded for an average of 88 days during screening and 133 days during randomisation.
Med študijo SET so bolniki opažanja v dnevnik zapisovali povprečno 88 dni med presejalnim obdobjem in 133 dni med randomizacijo.

Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
Randomizacija je bila razslojena glede na status BRAF in status PD-L1 tumorja ter najboljši odziv na predhodno zdravljenje z ipilimumabom.

The median duration of time from initial diagnosis to randomisation was 2.6 years in both the nivolumab and everolimus groups.
Mediano trajanje časa od začetne diagnoze do randomizacije je bilo 2,6 leta v obeh skupinah, v skupini z nivolumabom in skupini z everolimusom.

Randomisation was followed by a 12-week Natpar titration phase and a 12-week Natpar dose maintenance phase.
Randomizaciji sta sledili 12-tedensko obdobje titriranja zdravila Natpar in 12-tedensko obdobje vzdrževanja odmerka zdravila Natpar.

Tumour assessments were conducted 12 weeks after randomisation then every 6 weeks for the first year, and every 12 weeks thereafter.
Vrednotenje tumorja je bilo izvedeno 12 tednov po randomizaciji in se je v prvem letu nadaljevalo na vsakih 6 tednov, nato pa na vsakih 12 tednov.

Randomisation was stratified by prior trastuzumab treatment and number of prior treatments for metastatic disease.
Randomizacija je bila stratificirana po predhodnem zdravljenju s trastuzumabom in številom predhodnih zdravljenj zaradi metastatske bolezni.

The primary efficacy parameter of the trial was overall survival, defined as the time from randomisation to death from any cause.
Primarni parameter učinkovitosti kliničnega preskušanja je bilo celokupno preživetje, opredeljeno kot čas od randomizacije do smrti zaradi katerega koli vzroka.

Randomisation was stratified by sites of disease and by time from discontinuation of prior adjuvant anti-oestrogen therapy.
Randomizacija je bila stratificirana po mestu bolezni in po času od prenehanja predhodnega adjuvantnega antiestrogenskega zdravljenja.

A significant reduction in the number of HDDs and TAC occurred in some patients in the period between the initial visit(screening) and randomisation due to non-pharmacological effects.
Do pomembnega zmanjšanja števila HDDs in TAC je prišlo pri nekaterih bolnikih v obdobju od začetnega obiska(presejalni pregled) in randomizacije zaradi ne-farmakološkega učinka.

Randomisation was stratified by breast cancer type(operable, locally advanced, or inflammatory) and ER and/or PgR positivity.
Randomizacija je bila stratificirana glede na tip raka dojk(operabilen, lokalno napredovali ali vnetni) in glede na pozitivnost ER in PgR.

PFS was defined as the time from randomisation to the earliest date of disease progression or death from any cause, or to the date of censor.
Preživetje brez napredovanja(PFS) je bilo opredeljeno kot čas od randomizacije do najzgodnejšega datuma napredovanja bolezni ali smrti zaradi kakšnega koli vzroka ali pa do datuma krnjenja.

At randomisation, these patients consumed such a small amount of alcohol that there was little room for further improvement(floor effect).
Pri randomizaciji so ti bolniki zaužili tako majhne količine alkohola, da je bilo malo prostora za nadaljnje izboljšave(učinek tal).

At randomisation, active forms of vitamin D were reduced by 50% and patients were allocated to Natpar 50 micrograms daily or placebo.
Ob randomizaciji so zmanjšali odmerke aktivne oblike vitamina D za 50% in bolnike razdelili v skupino, ki je prejemala 50 mikrogramov zdravila Natpar na dan ali placebo.

Randomisation was stratified by geographic region, time to progression from the start of first-line therapy(< 6 months versus≥6 months) and disease measurability.
Randomizacija je bila stratificirana z geografsko regijo, časom do napredovanja bolezni od začetka zdravljenja prve izbire(< 6 mesecev v primerjavi z ≥6 mesecev) in merljivostjo bolezni.